Background: The study aimed to investigate hepatitis C virus (HCV) specific markers in chronically infected children. The main objective was to explore the patterns of marker variability.
Methods: HCV RNA, core antigen, anti-HCV IgM, and antibodies to individual viral proteins were detected using commercially available assays or experimental ELISA. RNA genotyping and recombination were performed by sequencing.
Results: HCV RNA and core antigen were detected in serum samples of all children (n=100). Anti-HCV IgM, anti-NS4AB IgG, and anti-NS5A IgG were revealed less often than antibodies to core and NS3 proteins. To elucidate the cause of this finding, all subjects were divided into 4 groups differing in hepatitis duration. It was anti-NS4AB only whose detection depended on the infection duration. A trend was established that the longer the hepatitis duration, the more frequently anti-HCV IgM was observed. No significant impact of HCV RNA load and NS4A/NS4B amino acid substitutions on anti-NS4AB IgG detection was found. The increase HCV genotype 3 was observed among children infected after 2000. The earliest case of infection caused by HCV intergenotype recombinant RF1_2k/1b was identified in a child vertically infected in 1997.
Conclusions: HCV genotypes and subtypes were found to be variable virus specific markers in children infected in 1997-2015. Over the period, there has been a trend to change the dominant HCV subtype and appearance of recombinant RF1_2k/1b in children. Among humoral markers, anti-NS4AB revealing is depended on chronic hepatitis C duration, while for anti-HCV IgM, only a trend was established. The detection of anti-NS4AB can be helpful in assessing the duration of chronic hepatitis C.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.23736/S2724-5276.21.06564-2 | DOI Listing |
IJID Reg
December 2024
Department 1: Infectious Diseases, Robert Koch Institute, Berlin, Germany.
Objectives: Following the outbreak of hepatitis E in camps for internally displaced persons (IDPs) in Borno State in 2017, we assessed hepatitis B, C, and E biomarkers (hepatitis B surface antigen [HBsAg], anti-HBC, anti-hepatitis E virus [HEV] immunoglobulin [Ig] G, and anti-HEV IgM) among IDPs in three camps in Borno State, Nigeria, to determine seroprevalence rates in these understudied populations.
Methods: A total of 454 IDPs, including pregnant women and breastfeeding mothers, were randomly selected, and their demographic, clinical, and epidemiological data were collected. Blood samples were tested for HBsAg and anti-hepatitis C virus (HCV) using rapid tests, anti-HEV IgM, and anti-HEV IgG using enzyme-linked immunosorbent assay.
Viruses
October 2024
Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, RJ, Brazil.
Background: Viral hepatitis is a disease that is more prevalent among individuals residing in remote regions and in contexts of social vulnerability. The objective of this study was to ascertain the seroprevalence of hepatitis A (HAV), B (HBV), and C (HCV) in vulnerable communities in the rural area of São João do Piauí (SJP), northern Brazil.
Methods: Immunoenzymatic assays were employed to detect the presence of anti-HAV (total and IgM), HBsAg, anti-HBc, anti-HBs, and anti-HCV serological markers in serum samples.
Virusdisease
September 2024
Hepatitis Research Center, Department of Virology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Am J Gastroenterol
October 2024
Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, Michigan, USA .
Introduction: The Revised Electronic Causality Assessment Method (RECAM) is an updated, electronic version of the Roussel Uclaf Causality Assessment Method (RUCAM) to diagnose drug-induced liver injury (DILI). The primary aim of this study was to compare RECAM vs RUCAM in patients with suspected DILI.
Methods: Patient encounters from October 1, 2015, to September 30, 2019, were searched for suspected DILI using ICD-10 K71 codes for toxic liver disease.
Rev Saude Publica
October 2024
Universidade Federal da Bahia. Instituto de Saúde Coletiva. Salvador, BA, Brasil.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!